Skip to main content

An update on an incident involving one of our systems

Hide
Quest Diagnostics

Insulin Resistance is Associated with Incident Prediabetes and Type 2 Diabetes in Normoglycemic Individuals

Insulin Resistance is Associated with Incident Prediabetes and Type 2 Diabetes in Normoglycemic Individuals

Authors: Louie JZ, Shiffman D, Meigs JB, Taylor SW, Melander O, Abbasi F, McPhaul MJ

Citation: Diabetes Metab Syndr. 2025 Dec 31;20(1):103372. doi: 10.1016/j.dsx.2025.103372. Online ahead of print.

Specialties: Endocrinology, Cardiology, Cardiovascular disease

Download key summary

Related content

Audio Podcast
Action From Insight: Tackling Insulin Resistance
Audio Podcast
The Insulin Resistance Revolution: The Key to Preventing Chronic Conditions
Audio Podcast
Instant Insight: Metabolic Risk Panel
Test FAQ
Insulin Intact LC MS MS
Publication
An HDL Proteomic Score Independently Predicts Incident Atherosclerotic Cardiovascular Disease
Publication
Association of MPO Levels With Cardiometabolic Disease Stratified by Atherosclerotic Cardiovascular Risk and Intensity of Therapy in a Workforce Population
On-Demand Webinar
Autoimmune Disease and Cardiometabolic Risk

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only. May include AI-generated and/or AI-modified imagery.